Worm.com

SYDNEY (AFP) — A leading HIV expert urged Wednesday drugs giants to focus on developing anti-retroviral medicines for children, after research showed early treatment of babies can reduce death rates by 75 percent.

As the International AIDS Society conference wrapped up in Sydney, US researcher Annette Sohn said some 780,000 HIV positive children globally needed anti-retroviral medicines but only 15 percent of them were receiving treatment.

Sohn, an assistant professor at the University of California San Francisco’s paediatric infectious diseases division, said there was also a lack of specialised medicine developed for HIV positive children.

She said that children’s medical treatment often consisted of health professionals simply breaking up adult pills into what they hoped was child-sized doses.

“Better generic paediatric anti-retrovirals that are both potent enough to achieve sustained clinical and virological improvement and have limited long-term metabolic side effects are urgently needed,” …

Information provided by: Findarticles.com

DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c63667) has announced the addition of Infections - Herpes Simplex Virus Infection Drug Pipeline Report to their offering.

"Infections - Herpes Simplex Virus Infection Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of herpes simplex virus infection drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

* Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.

* Keep track of your competitors and partners by better understanding their product pipeline.

* Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.

* Maintain a critical competitive advantage.

Contents:

UPCOMING PATENT EXPIRES BY THERAPY AREA
 Herpes Simplex Virus Infection Pipeline Overview
-% of Projects (By Phase of Development)
-No. of Projects by Phase of Development
-Marketed Products Vs. Pipeline Products
-Company Overview - Pipeline Projects
-Company Overview - Pipeline Projects
-Legend
-Top 20 companies in late stage Herpes Simplex Virus Infection
  Projects
-Top 20 companies in early stage Herpes Simplex Virus Infection
  Projects
 Full Pipeline View
-Pre Clinical Pipeline View
-Phase II Pipeline View
-Phase III Pipeline View

For more information visit http://www.researchandmarkets.com/reports/c63667

Source: Life Science Analytics

COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com